Oncology Corporate Profile
Axelar AB is a Swedish biotech company founded in 2003. The company is developing insulin-like growth factor-1 (IGF-1) receptor inhibitors for treatment of cancer and other diseases. Axelar is part of the Karolinska Development portfolio of companies.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|AXL1717||insulin-like growth factor-1 (IGF-1) receptor inhibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|AXL1717||insulin-like growth factor-1 (IGF-1) receptor inhibitor||Various cancer types||I|
View additional information on product candidates here »